MIF-Dependent Control of Tumor Immunity.
MIF-Dependent Control of Tumor Immunity.
复制标题
肿瘤免疫的MIF依赖性控制。
DOI：
10.3389/fimmu.2020.609948
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Mitchell RA
中科院分区：
文献类型：
--
作者：
Noe JT;Mitchell RA
巨噬细胞移动抑制因子（MIF）最初被鉴定为T淋巴细胞诱导的巨噬细胞运动抑制剂，此后发现几乎每种免疫细胞类型都表达，并且在大多数实体和血行性恶性肿瘤中过表达。它定位于细胞外和细胞内区室，并与十几种不同的细胞表面和细胞内蛋白质发生物理相互作用。尽管经典地与促炎性先天免疫应答相关并表征为促炎性先天免疫应答的介体，但最近的研究表明，在恶性疾病环境中，MIF有助于先天和适应性免疫细胞类型中的抗炎、免疫逃避和免疫耐受表型。本文综述了MIF在肿瘤特异性先天性和适应性免疫反应中的作用，并试图在正常生理学中协调这些多种多样的功能。
Initially identified as a T lymphocyte-elicited inhibitor of macrophage motility, macrophage migration inhibitory factor (MIF) has since been found to be expressed by nearly every immune cell type examined and overexpressed in most solid and hematogenous malignant cancers. It is localized to both extracellular and intracellular compartments and physically interacts with more than a dozen different cell surface and intracellular proteins. Although classically associated with and characterized as a mediator of pro-inflammatory innate immune responses, more recent studies demonstrate that, in malignant disease settings, MIF contributes to anti-inflammatory, immune evasive, and immune tolerant phenotypes in both innate and adaptive immune cell types. This review will summarize the studies describing MIF in tumor-specific innate and adaptive immune responses and attempt to reconcile these various pleiotropic functions in normal physiology.